Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
|Videos|July 27, 2017
1990s to Today: How Has Generating Interest for the Response to HIV and AIDS Changed?
Author(s)Contagion Editorial Staff
Jake Glaser discusses how generating interest for the response to HIV and AIDS has changed since the 1990s.
Advertisement
Jake Glaser, Founder, Modern Advocate; Ambassador, Elizabeth Glaser Pediatric AIDS Foundation and Member, End AIDS Coalition, discusses how generating interest for the response to HIV and AIDS has changed since the 1990s.
Interview Transcript (slightly modified for readability):
“The difference in generating the attention and the response to HIV and AIDS from the 1990s [to today] is a 180° switch from what we knew. We [now] live in a world of unprecedented technology and connectivity; we have the amazing tool of social media. The opportunity to deliver information and grow education is much easier, and much more real-time than it ever was. It is a very positive thing (no pun intended) to be able to educate a very large population of people in a very short period of time with the right strategy. That’s something that the
But, being able to find collaborations, the right influencers, and the right mediums to be able to speak about awareness...to be able to educate on prevention and to let people know the status of HIV in the world today is something that has evolved in incredible ways. We live in a very positive reality now and in a very promising world, to be able to affect a new generation in a way that is going to, hopefully, ensure that they will not have to confront, or deal with, HIV in the future.”
Advertisement
Related to this article
Dr. Reddy’s generic twice-yearly lenacapavir received FDA tentative approval for HIV PrEP. It is expected to cost $40 a year in 120 low- and middle-income countries (LMICs), with first supplies due by the end of 2026.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
Switching to once-daily bictegravir/lenacapavir kept adverse event rates similar to comparators and metabolic markers stable across comorbidity groups in ARTISTRY-1 and -2.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
David Altarac, MD, discusses 2025 SENTRY data, ESBL considerations in empiric therapy, and where ceftobiprole fits alongside ceftaroline in S aureus bacteremia.
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
2
Half of Long COVID Patients Substantially Improve Within 3 years
3
From Pathogen to Infectious Disease Diagnosis: Reflex Testing Targets Hepatitis D Gap
4
Early Metformin Linked to 53% Lower Risk of Long COVID or Death
5